| Overview |
| bs-12757R-BF350 |
| Vimentin (Ser55) Polyclonal Antibody, AbBy Fluor® 350 Conjugated |
| WB, FCM |
| Human |
| Horse |
| Specifications |
| AbBy Fluor® 350 |
| Rabbit |
| KLH conjugated synthesised phosphopeptide derived from human Vimentin around the phosphorylation site of Ser55 |
| Ser55 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7431 |
| P08670 |
| Cytoplasm |
| Vimentin (phospho S55); p-Vimentin (phospho S55); CTRCT30; Epididymis luminal protein 113; FLJ36605; HEL113; VIM; VIME_HUMAN; vimentin. |
| This gene encodes a member of the intermediate filament family. Intermediate filamentents, along with microtubules and actin microfilaments, make up the cytoskeleton. The protein encoded by this gene is responsible for maintaining cell shape, integrity of the cytoplasm, and stabilizing cytoskeletal interactions. It is also involved in the immune response, and controls the transport of low-density lipoprotein (LDL)-derived cholesterol from a lysosome to the site of esterification. It functions as an organizer of a number of critical proteins involved in attachment, migration, and cell signaling. Mutations in this gene causes a dominant, pulverulent cataract.[provided by RefSeq, Jun 2009] |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz